BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/4/2024 10:57:41 AM | Browse: 78 | Download: 76
 |
Received |
|
2023-11-03 10:12 |
|
Peer-Review Started |
|
2023-11-03 10:14 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-12-06 08:04 |
|
Revised |
|
2023-12-17 17:46 |
|
Second Decision |
|
2024-01-08 00:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2024-01-16 05:33 |
|
Articles in Press |
|
2024-01-16 05:33 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-01-30 02:58 |
|
Publish the Manuscript Online |
|
2024-02-04 10:57 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Editorial |
| Article Title |
Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mahmoud Nassar, Ajay Chaudhuri, Husam Ghanim and Paresh Dandona |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mahmoud Nassar, MD, MSc, PhD, Doctor, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu |
| Key Words |
Type 1 diabetes; Semaglutide; Glucagon-like peptide-1 receptor agonists; Insulin therapy; Autoimmune response; Blood glucose monitoring; Β-cell preservation; Early screening; Teplizumab; Randomized controlled trials |
| Core Tip |
New research suggests a novel approach to treating type 1 diabetes (T1D) by using glucagon-like peptide-1 receptor agonists, specifically semaglutide, to significantly improve blood glucose control and potentially slow the progression of the disease in newly diagnosed patients. This strategy, which leads to less insulin dependence and better metabolic markers, could change the way T1D is managed in a big way. At the same time, the study supports early T1D risk screening, especially in groups with high risk, so that early interventions can be made, evaluating the benefits against the possible emotional and financial effects. This dual approach shows that there are bright futures for improving the lives of patients with T1D. |
| Publish Date |
2024-02-04 10:57 |
| Citation |
Nassar M, Chaudhuri A, Ghanim H, Dandona P. Glucagon-like peptide-1 receptor agonists as a possible intervention to delay the onset of type 1 diabetes: A new horizon. World J Diabetes 2024; 15(2): 133-136 |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i2/133.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i2.133 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
